Oppenheimer analyst Suraj Kalia upgraded AtriCure to Outperform from Perform with a $32 price target. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See the top stocks recommended by analysts >> Read More on ATRC: Oppenheimer medical devices analysts hold analyst/industry conference call Disclaimer & DisclosureReport an Issue